India Globalization Capital, Inc. (AMEX:IGC) has received a no objection letter from Health Canada for approval of its trial, “A phase 2, multi-center, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease.” The no objection letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to proceed with phase 2 trials in Canada.

Ram Mukunda, CEO of IGC, stated, “We are pleased to have received this no objection letter from Health Canada, which allows us to begin phase 2 trials on our …

Full story available on Benzinga.com